论文部分内容阅读
目的评价舒利迭即吸入型糖皮质激素(ICS)和长效β2受体激动剂(LABA)联合吸入对慢性阻塞性肺疾病(COPD)急性发作期患者的疗效。方法41例COPD急性发作期患者随机分为试验组和对照组。试验组(21例)在常规消炎祛痰的同时给予ICS/LABA混合吸入剂(舒利迭)吸入,每次50μg/500μg,2次/d;对照组(20例)给予常规消炎祛痰治疗。2组疗程均为20d。对比2组治疗前后肺功能变化。结果41例患者全部完成本试验。2组FEV1/FVC和FEV1%预计值分别较治疗前明显升高,差异有统计学意义(P均<0.05);治疗后试验组FEV1/FVC和FEV1%预计值分别高于对照组,差异有统计学意义(P均<0.05)。结论COPD急性发作期患者联合吸入ICS和LABA能明显改善肺功能,减轻症状,提高生活质量。
Objective To evaluate the efficacy of seretide in combination with inhaled glucocorticoid (ICS) and long-acting β2 agonist (LABA) in patients with acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods 41 cases of acute exacerbation of COPD were randomly divided into experimental group and control group. The experimental group (n = 21) was given ICS / LABA inhalation (50mg / 500μg, twice daily) at the same time of routine antiphlogistic and expectorant treatment. The control group (20 cases) were given routine antiphlogistic and expectorant treatment . 2 groups of treatment are 20d. The changes of lung function in two groups before and after treatment were compared. Results All 41 patients completed the test. The predicted values of FEV1 / FVC and FEV1% in the two groups were significantly higher than those before treatment (P <0.05), and the predicted values of FEV1 / FVC and FEV1% in the experimental group were higher than those in the control group Statistical significance (P <0.05). Conclusion Combined inhalation of ICS and LABA in patients with acute exacerbation of COPD can significantly improve pulmonary function, relieve symptoms and improve quality of life.